<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7111EF10-B5DF-4DA9-8324-2B55178F7871"><gtr:id>7111EF10-B5DF-4DA9-8324-2B55178F7871</gtr:id><gtr:name>Uni of Illinois at Urbana Champaign</gtr:name><gtr:address><gtr:line1>Admissions and Records</gtr:line1><gtr:line2>901 West Illinois Street</gtr:line2><gtr:postCode>61801</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/581E0F16-A0E6-4EE1-9CC3-A5DCE995756E"><gtr:id>581E0F16-A0E6-4EE1-9CC3-A5DCE995756E</gtr:id><gtr:name>University of Zagreb</gtr:name><gtr:address><gtr:line1>Trg marsala Tita 14</gtr:line1><gtr:postCode>10000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D6C3234E-5048-4AA0-A116-0CAC51569B2D"><gtr:id>D6C3234E-5048-4AA0-A116-0CAC51569B2D</gtr:id><gtr:name>University of Queensland</gtr:name><gtr:address><gtr:line1>University of Queensland</gtr:line1><gtr:line4>Brisbane</gtr:line4><gtr:line5>Queensland 4972</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F487F48E-D3D4-4CCF-8408-9DAF3FF76EFE"><gtr:id>F487F48E-D3D4-4CCF-8408-9DAF3FF76EFE</gtr:id><gtr:name>University of Ioannina</gtr:name><gtr:address><gtr:line1>University of Ioannina</gtr:line1><gtr:postCode>45510</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7111EF10-B5DF-4DA9-8324-2B55178F7871"><gtr:id>7111EF10-B5DF-4DA9-8324-2B55178F7871</gtr:id><gtr:name>Uni of Illinois at Urbana Champaign</gtr:name><gtr:address><gtr:line1>Admissions and Records</gtr:line1><gtr:line2>901 West Illinois Street</gtr:line2><gtr:postCode>61801</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/581E0F16-A0E6-4EE1-9CC3-A5DCE995756E"><gtr:id>581E0F16-A0E6-4EE1-9CC3-A5DCE995756E</gtr:id><gtr:name>University of Zagreb</gtr:name><gtr:address><gtr:line1>Trg marsala Tita 14</gtr:line1><gtr:postCode>10000</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D6C3234E-5048-4AA0-A116-0CAC51569B2D"><gtr:id>D6C3234E-5048-4AA0-A116-0CAC51569B2D</gtr:id><gtr:name>University of Queensland</gtr:name><gtr:address><gtr:line1>University of Queensland</gtr:line1><gtr:line4>Brisbane</gtr:line4><gtr:line5>Queensland 4972</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F487F48E-D3D4-4CCF-8408-9DAF3FF76EFE"><gtr:id>F487F48E-D3D4-4CCF-8408-9DAF3FF76EFE</gtr:id><gtr:name>University of Ioannina</gtr:name><gtr:address><gtr:line1>University of Ioannina</gtr:line1><gtr:postCode>45510</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0B002523-689F-4F56-9A66-8D972B7F0CFF"><gtr:id>0B002523-689F-4F56-9A66-8D972B7F0CFF</gtr:id><gtr:firstName>Jan</gtr:firstName><gtr:surname>Domin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500936"><gtr:id>CB53240E-9F6F-49CF-B79D-C62BAB7FAC5C</gtr:id><gtr:title>Regulation of cell morphology, migration and adhesion by class II phosphoinositide 3-kinase enzymes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500936</gtr:grantReference><gtr:abstractText>In this project we are trying to better understand what makes human cells move. This is a very important question because large numbers of cancer patients die each day worldwide because tumour cells leave the original site of disease to spread throughout their body. This spreading makes it difficult to provide a cure by surgery alone if the cancer is discovered late.
Our work focuses on breast cancer since these tumour cells often move faster when they meet a protein called epidermal growth factor or EGF. Once this happens, proteins inside the tumour, act in a series of steps to make the cells move. We have previously shown that one of these steps involves a protein called PI3K-C2b. At the moment we know little about how PI3K-C2b acts inside cells to increase their speed.
We will grow human breast cancer cells in the lab and record how they move after EGF treatment over many hours using a microscope and video camera. We will then see what happens to cancer cells that make more PI3K-C2b protein or we block its production. This will show us if PI3K-C2b can be used as a target for new medicines against cancer.</gtr:abstractText><gtr:technicalSummary>Phosphatidylinositol (PtdIns)(3,4,5)P3 has been shown to play a pivotal regulatory role in the re-organisation of actin filaments in response to integrin, growth factor and chemokine receptor stimulation. In recent years, several downstream targets of PtdIns(3,4,5)P3 have been identified and the mechanisms responsible for its effects on actin filaments elucidated. However, the full spectrum of phosphoinositide 3-kinase (PI3K) enzymes responsible for the production of PtdIns(3,4,5)P3 remains unclear as is the contribution made by other 3-phophoinositides to actin filament reorganisation. I have demonstrated that stable expression of the class II enzyme PI3K-C2beta in human embryonic kidney (HEK) cells decreased their adhesion and increased their migration. Consistent with these effects, PI3K-C2beta decreased expression of both the alpha4 and beta1 integrin subunits that together form VLA4 that binds ICAM1 and fibronectin. PI3K-C2beta expression also increases actin filaments at the cell cortex and actin rich lamellipodia and filopodia in HEK293 cells plated onto fibronectin. Each of these PI3K-C2beta mediated effects were dependent upon its catalytic activity. Critically, co-expression of 2xFYVE domains that selectively bind PtdIns(3)P inhibited the PI3K-C2beta mediated effects on filopodia and lamellipodia formation. These data domonstrate that not only might the class II PI3K enzymes form novel mediators of cell migration, the molecular mechanism responsible require elucidation. Consequently, in this proposal we will:

1. Compare and contrast the effects of acute versus chronic expression of PI3K-C2beta on actin filament reorganisation, integrin expression, migration and vesicle transport.
2. Establish the effect of topically administered or microinjection PtdIns(3)P on actin filaments
3. Identify the molecular mechanisms downstream of 3-phoshoinositide production that mediate the effects of PI3K-C2beta on actin assembly, cell migration and morphology.
4. Evaluate the effect of chronic PI3K-C2beta expression in growth factor dependent chemotaxis in vitro and xenograft metastasis in vivo</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-24</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-25</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>226575</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Queensland</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>FM</gtr:description><gtr:id>DC3F1CC0-DA6D-40DB-BF63-F6D7E8DA5E7F</gtr:id><gtr:impact>18843041</gtr:impact><gtr:outcomeId>059CC529DBD-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input, microscopy</gtr:partnerContribution><gtr:piContribution>Intellectual input, reagents, biochemical analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>RM</gtr:description><gtr:id>6D57D82F-EB86-4469-900E-2142EA198453</gtr:id><gtr:impact>Project grant</gtr:impact><gtr:outcomeId>EACADA61A23-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input, technical support</gtr:partnerContribution><gtr:piContribution>Intellectual input, biochemical analysis, reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ioannina</gtr:collaboratingOrganisation><gtr:country>Greece, Hellenic Republic</gtr:country><gtr:description>KS</gtr:description><gtr:id>8AAC2CE0-A473-4370-A34E-D2DC86AAD227</gtr:id><gtr:impact>19950162</gtr:impact><gtr:outcomeId>1D5DE198145-1</gtr:outcomeId><gtr:partnerContribution>Providing intellectual input, chemical libraries and lead compounds</gtr:partnerContribution><gtr:piContribution>Intellectual input, biochemical analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zagreb</gtr:collaboratingOrganisation><gtr:country>Croatia, Republic of</gtr:country><gtr:description>HB</gtr:description><gtr:id>58E95B1F-D501-477D-B3F0-FAD21414D3B8</gtr:id><gtr:impact>19496756</gtr:impact><gtr:outcomeId>43E4EE83C0A-1</gtr:outcomeId><gtr:partnerContribution>Expertise in the analysis of proteins in nuclei</gtr:partnerContribution><gtr:piContribution>Intellectual input, providing laboratory access, reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Illinois</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>JO</gtr:description><gtr:id>55374A2D-0EF6-4213-A88F-126483D90F13</gtr:id><gtr:impact>17875942</gtr:impact><gtr:outcomeId>A56473B4A95-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input, cDNA and antibodies</gtr:partnerContribution><gtr:piContribution>Intellectual input, cDNA and antibodies, biochemical analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>31D9576C-4DCA-472A-BFF6-D57925F83A9E</gtr:id><gtr:impact>Providing an overview of cancer research and career options in Biomedical science

Raising public awareness and improving career advice</gtr:impact><gtr:outcomeId>BFE936E7A74</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>14C16D72-E894-4908-AE95-B47D6FD0B516</gtr:id><gtr:impact>The post doc researcher returned to her secondary school to promote careers in science

Raised significant interest in reading a biochemical science/medicine at degree level</gtr:impact><gtr:outcomeId>24AE7BA6927</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Diabetes UK, Project Grant</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>1159843C-5A6D-4565-8218-F0EEA37E28DC</gtr:id><gtr:outcomeId>84E9C7F89700</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Validated breast cancer cell line and conditions to study growth factor induced scatter of breast cancer cells in vitro</gtr:description><gtr:id>D4FBEDD8-F2A5-477C-AFFA-47E3C65DF65E</gtr:id><gtr:impact>Manuscript</gtr:impact><gtr:outcomeId>B70A6DD2E22</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Scatter assay</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>validating oligonuleotides to silence PI3K gene expression</gtr:description><gtr:id>D08D64CF-1AC9-4F31-8BCA-643FCA3EAA52</gtr:id><gtr:impact>Publication</gtr:impact><gtr:outcomeId>E1138BE532B</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>siRNA</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B3F1AC15-4210-4F16-B648-80986FE5FF2B</gtr:id><gtr:title>Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study.</gtr:title><gtr:parentPublicationTitle>Neoplasia (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ede33a7bbd21930398f44b14eff4e3e"><gtr:id>0ede33a7bbd21930398f44b14eff4e3e</gtr:id><gtr:otherNames>El Sheikh SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1476-5586</gtr:issn><gtr:outcomeId>585d634a9699b9.31584283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3ED2E27-73E4-4A88-842B-9258A8DD42D9</gtr:id><gtr:title>Ca2+-regulated pool of phosphatidylinositol-3-phosphate produced by phosphatidylinositol 3-kinase C2alpha on neurosecretory vesicles.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a39dbe91787f366100ced8fe3783c890"><gtr:id>a39dbe91787f366100ced8fe3783c890</gtr:id><gtr:otherNames>Wen PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn><gtr:outcomeId>FAE4096F34D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4342BDE9-A337-4605-82E0-1795FE7AA767</gtr:id><gtr:title>Requirement for class II phosphoinositide 3-kinase C2alpha in maintenance of glomerular structure and function.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f2934629971b5f98c0a99ebbaff6b1a"><gtr:id>9f2934629971b5f98c0a99ebbaff6b1a</gtr:id><gtr:otherNames>Harris DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>DqVhFUgcdDn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8067925-D15E-43A2-B81F-FDCC83AC2B6F</gtr:id><gtr:title>Epidermal growth factor stimulates translocation of the class II phosphoinositide 3-kinase PI3K-C2beta to the nucleus.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/748cbe79632c63a14ab367f4a1a9ad71"><gtr:id>748cbe79632c63a14ab367f4a1a9ad71</gtr:id><gtr:otherNames>Banfic H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>BC61DC75308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77A11655-949D-484F-BB09-324EB210E3EB</gtr:id><gtr:title>Human pancreatic secretory trypsin inhibitor stabilizes intestinal mucosa against noxious agents.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43bf62fa85e499782ba86fe6a3f8f3d0"><gtr:id>43bf62fa85e499782ba86fe6a3f8f3d0</gtr:id><gtr:otherNames>Marchbank T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>5E05D2BB7DD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AD6656D-4AF3-4507-8B69-9E2ED71A02AA</gtr:id><gtr:title>The inositol 5-phosphatase SHIP2 regulates endocytic clathrin-coated pit dynamics.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/558d8bcd4a077f19633a5ee493215f0a"><gtr:id>558d8bcd4a077f19633a5ee493215f0a</gtr:id><gtr:otherNames>Nakatsu F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>FGcNMiQY32R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>842513EF-53BD-4C07-AC54-9F322EA364E9</gtr:id><gtr:title>Hyperglycemia causes renal cell damage via CCN2-induced activation of the TrkA receptor: implications for diabetic nephropathy.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6086ff36a96bd172759fbc24dc10cd6a"><gtr:id>6086ff36a96bd172759fbc24dc10cd6a</gtr:id><gtr:otherNames>Fragiadaki M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>pm_16601_21_22586581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08E5D1AC-2491-4251-B844-95F543F22BE4</gtr:id><gtr:title>Insulin-feedback via PI3K-C2alpha activated PKBalpha/Akt1 is required for glucose-stimulated insulin secretion.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94a094d7ace7591a015da68a32bfb453"><gtr:id>94a094d7ace7591a015da68a32bfb453</gtr:id><gtr:otherNames>Leibiger B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>pm_16601_21_20061534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>008C60A4-C8D4-4122-B1FB-D5C363704E26</gtr:id><gtr:title>Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer-A Pilot Study</gtr:title><gtr:parentPublicationTitle>Neoplasia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbd996d91bfc0b29277a906e562c6947"><gtr:id>dbd996d91bfc0b29277a906e562c6947</gtr:id><gtr:otherNames>Sheikh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>5a6f07b14fb1e6.51178151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF354F33-A841-41D7-86D9-81053A25E1E4</gtr:id><gtr:title>Mannose receptor interacts with Fc receptors and is critical for the development of crescentic glomerulonephritis in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d66c378821320bc34d039c1990b8a291"><gtr:id>d66c378821320bc34d039c1990b8a291</gtr:id><gtr:otherNames>Chavele KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>pm_16601_21_20407205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F054EE5-13E3-4F6A-914B-2F2C6D7F7A88</gtr:id><gtr:title>Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da0c192f6b66fbfd6add30530d39b5ab"><gtr:id>da0c192f6b66fbfd6add30530d39b5ab</gtr:id><gtr:otherNames>Behmoaras J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5752D168B68</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABC076BE-CAB2-4E6E-B7BF-623898FF3EE6</gtr:id><gtr:title>Regulation of neuron survival through an intersectin-phosphoinositide 3'-kinase C2beta-AKT pathway.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79b4ab8744feb67049a9e33f6ee74711"><gtr:id>79b4ab8744feb67049a9e33f6ee74711</gtr:id><gtr:otherNames>Das M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>B62CF87471E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF5C917A-5929-4A26-8F7C-2520880B5939</gtr:id><gtr:title>Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b547703bc2ca7a8c9075e2eba06909e"><gtr:id>6b547703bc2ca7a8c9075e2eba06909e</gtr:id><gtr:otherNames>Skobridis K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>DAE1CA26419</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500936</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>